SXTP - 60 DEGREES PHARMACEUTICALS, INC.

2.87
1.072   37.338%

Share volume: 84,925,492
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.80
1.07
0.60%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 50%
Liquidity 75%
Performance 35%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
62.15%
1 Month
96.58%
3 Months
173.33%
6 Months
169.46%
1 Year
991.25%
2 Year
-38.68%
Key data
Stock price
$2.87
P/E Ratio 
0.00
DAY RANGE
$2.35 - $4.41
EPS 
-$13.50
52 WEEK RANGE
$0.09 - $4.41
52 WEEK CHANGE
$981.79
MARKET CAP 
2.932 M
YIELD 
N/A
SHARES OUTSTANDING 
1.768 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-24-2025
NEXT EARNINGS DATE
04-15-2025
BETA 
3.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,152,139
AVERAGE 30 VOLUME 
$3,891,533
Company detail
CEO: Geoffrey Dow
Region: US
Website: 60degreespharma.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a growth-oriented specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. Our principal executive offices are located at 1025 Connecticut Avenue NW Suite 1000, Washington, D.C.

Recent news

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the signing of a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently appr

Read more

60 Degrees Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

60 Degrees Pharmaceuticals ( NASDAQ:SXTP ) Full Year 2024 Results Key Financial Results Revenue: US$681.3k (up 169...

Read more

60 Degrees Pharmaceuticals Announces 2024 Annual Results

FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the 2024 fiscal year, ended December 31, 2024. Financial Highlights for the Fiscal Year Ended Decembe

Read more